(Q44439070)

3 December 2017

title

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma (English)

1 reference

3 December 2017

Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma* (English)

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

main subject

phase II clinical trial

0 references

0 references

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

author name string

Keith M. Skubitz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743981

1 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12743981

1 January 2024

publication date

1 April 2003

1 reference

full work available at URL

3 December 2017

http://www.tandfonline.com/doi/pdf/10.1081/CNV-120016412

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

1 reference

3 December 2017

volume

21

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

167-176

1 reference

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Dose response evaluation of adriamycin in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Lack of vesicant injury following extravasation of liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Phase II evaluation of adriamycin in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016412

21 January 2018

2

54

987

Gabizon A.

1994

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

6

52

6774

Huang S.K.

1992

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

Cancer Treatment Reports

21

60

199

Gottlieb J.A.

1976

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

Cancer Treatment Reports

25

71

971

Samuels B.L.

1987

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

Cancer Treatment Reports

36

64

93

Yap B.S.

1980

1 reference

https://api.crossref.org/works/10.1081/CNV-120016412

1 January 2024

Identifiers

1 reference

3 December 2017

1 reference